683 Capital Management’s Pyxis Oncology PYXS Stock Holding History

683 Capital Management’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Sell	459,367 -436,896	-49%	-$835K	0.07%	117
2026 Q1	$1.31M	Buy	896,263 +4,353	+0.5%	+$6.56K	0.07%	129
2025 Q4	$1.03M	Buy	891,910 +366,910	+70%	+$1.29M	0.04%	139
2025 Q3	$1.17M	Sell	525,000 -20,000	-4%	-$28.8K	0.06%	119
2025 Q2	$600K	Sell	545,000 -5,000	-0.9%	-$5.63K	0.04%	117
2025 Q1	$539K	Buy	550,000 +135,000	+33%	+$180K	0.04%	127
2024 Q4	$647K	Buy	415,000 +344	+0.1%	+$992	0.04%	136
2024 Q3	$1.52M	Buy	+414,656	New	+$1.45M	0.12%	95

Other funds holding PYXS

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's PYXS Position: Q2 2026 in Review

683 Capital Management reduced its Pyxis Oncology (PYXS) stake by 49% in Q2 2026, selling an estimated $835K and leaving 459,367 shares worth $1.38M. The position accounts for 0.07% of the portfolio, ranked #117.

683 Capital Management first reported a position in PYXS in Q3 2024 and has held it in 8 quarters since. The position peaked at $1.52M in Q3 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

683 Capital Management held 459,367 shares of Pyxis Oncology worth $1.38M as of Q2 2026.
683 Capital Management sold 436,896 Pyxis Oncology shares in Q2 2026, an estimated $835K.
Pyxis Oncology made up 0.07% of 683 Capital Management's portfolio in Q2 2026, its #117 holding.
683 Capital Management first reported a position in Pyxis Oncology in Q3 2024 and has held it in 8 quarters since.
683 Capital Management's Pyxis Oncology position peaked at $1.52M in Q3 2024.
76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.